ReviewAllergy, asthma & immunology research2016
Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury.
Review in Allergy, asthma & immunology research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Advancing drug safety in psychiatry: insights from pharmacogenomics of hypersensitivity reactions.Frontiers in pharmacology · 2025Review
- Drug hypersensitivity reactions: review of the state of the science for prediction and diagnosis.Toxicological sciences : an official journal of the Society of Toxicology · 2024Review
- Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use.International journal of molecular sciences · 2023Review
- An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation.International journal of molecular sciences · 2023Review
- Mesenchymal stromal cell-dependent immunoregulation in chemically-induced acute liver failure.World journal of stem cells · 2021Review
- Topic Evolution Analysis for Omics Data Integration in Cancers.Frontiers in cell and developmental biology · 2021Article
- Active Pharmacovigilance of Drug-Induced Liver Injury Using Electronic Health Records.Allergy, asthma & immunology research · 2020Article
- Fenofibrate-induced hepatotoxicity: A case with a special feature that is different from those in the LiverTox database.Journal of clinical pharmacy and therapeutics · 2020Article
- Anastrozole-induced liver injury after a prolonged latency: a very rare complication of a commonly prescribed medication.BMJ case reports · 2019Article
- Dyslipidemia is a Risk Factor for the Incidence and Severity of Drug-Induced Liver Injury (DILI): A Retrospective Population-Based Study in China.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019.Frontiers in pharmacology · 2019Review
- Incidence, clinical features, and risk factors of fluoroquinolone-induced acute liver injury: a case-control study.Therapeutics and clinical risk management · 2019Article
- Elevation of the serum liver enzyme levels during tolvaptan treatment in patients with autosomal dominant polycystic kidney disease (ADPKD).Clinical and experimental nephrology · 2018Article
- Mechanisms of Inflammatory Liver Injury and Drug-Induced Hepatotoxicity.Current pharmacology reports · 2018Article
- Genetic Basis of Delayed Hypersensitivity Reactions to Drugs in Jewish and Arab Populations.Pharmaceutical research · 2018Review
- Why Drugs Fail in Late Stages of Development: Case Study Analyses from the Last Decade and Recommendations.The AAPS journal · 2018Article
- Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.Omics : a journal of integrative biology · 2017Article
- Novel circulating- and imaging-based biomarkers to enhance the mechanistic understanding of human drug-induced liver injury.Journal of clinical and translational research · 2017Review
- Mechanistic Modelling of Drug-Induced Liver Injury: Investigating the Role of Innate Immune Responses.Gene regulation and systems biology · 2017Article
- A case of levocetirizine-induced liver injury.Clinical and molecular hepatology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Drug-induced liver injury (DILI) is a major concern for public health, as well as for drug development in the pharmaceutical industry, since it can cause liver failure and lead to drug withdrawal from the market and black box warnings. Thus, it is important to identify biomarkers for early prediction to increase our understanding of mechanisms underlying DILI that will ultimately aid in the exploration of novel therapeutic strategies to prevent or manage DILI. DILI can be subdivided into 'intrinsic' and 'idiosyncratic' categories, although the validity of this classification remains controversial. Idiosyncratic DILI occurs in a minority of susceptible individuals with a prolonged latency, while intrinsic DILI results from drug-induced direct hepatotoxicity over the course of a few days. The rare occurrence of idiosyncratic DILI requires multicenter collaborative investigations and phenotype standardization. Recent progress in research on idiosyncratic DILI is based on key developments in 3 areas: (1) newly developed high-throughput genotyping across the whole genome allowing for the identification of genetic susceptibility markers, (2) new mechanistic concepts on the pathogenesis of DILI revealing a key role of drug-responsive T lymphocytes in the immunological response, and (3) broad multidisciplinary approaches using different platform "-omics" technologies that have identified novel biomarkers for the prediction of DILI. An association of a specific human leukocyte antigen (HLA) allele with DILI has been reported for several drugs. HLA-restricted T-cell immune responses have also been investigated using lymphocytes and T-cell clones isolated from patients. A microRNA, miR-122, has been discovered as a promising biomarker for the early prediction of DILI. In this review, we summarize recent advances in research on idiosyncratic DILI with an understanding of the key role of adaptive immune systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.